关键词: 胆道系统肿瘤, 免疫治疗, 综合治疗

Abstract: Progress of immunotherapy in advanced biliary tract cancers        CHEN Lu, SONG Tian-qiang, LI Qiang. Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital，Tianjin 300060，China
Corresponding authors: CHEN Lu, E-mail：chenlu@tmu.edu.cn; SONG Tian-qiang, E-mail：tjchi@hotmail.com; LI Qiang, E-mail：liqiang4016@163.com
Abstract    There is a lack of clinical treatment strategies for advanced and metastatic biliary tract cancers (BTCs). Chemotherapy is still the main treatment for advanced BTCs. Gemcitabine combined with cisplatin is the first-line chemotherapeutic regimen of advanced BTCs, and no second-line regimen is available now. Immunotherapy is a promising treatment; its application in BTCs is still in the initial stage and need further exploration. Some phase I/II clinical trials associated with immunotherapy strategies represented by immunosuppressive checkpoint inhibitors have shown good safety, tolerability and antitumor activity. However, the low incidence rate and high heterogeneity of BTCs also restrict the discovery and clinical application of biomarkers in immunotherapy, which limits the development of prospective clinical trials based on large samples. Whether immunotherapy based on monotherapy or combination therapy can bring better survival benefits for patients with advanced BTCs still needs to wait for the conclusion of more phase III clinical trials, and a large number of clinical trials and practices need to be carried out to further verify.

Key words: biliary tract cancers, immunotherapy, integrated therapy